Many patients with IBD report persisting symptoms, despite resolution of the inflammatory process. Although by definition, a ...

In the wake of the presidential election, another change in interest rates and continued news about geopolitical unrest, the appeal of blue-chip stocks is stronger than ever. That' ...

To help you in your search, three Fool.com contributors have pulled together reports on a few opportunities they think are ...

However, arguably the next best thing is for a company to belong to the elite group known as Dividend Kings. To qualify, a ...

You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

"Year to date" sales for 2021, 2022, 2023, and 2024 sales are shown in series at the top of the table and then just below a comparison of 2024 versus 2023 and 2024 versus 2022 is displayed. This ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.

dividend-frequency { font-size: 12px; color: #6c757d; } Through a meticulous analysis of AbbVie, we can observe the following trends: A Price to Earnings ratio of 70.21 significantly below the ...

NORTH CHICAGO, Ill. and BRANFORD, Conn., Oct. 31, 2024 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

The neurological biomarkers market is expanding as neurological disorders, including dementia and Parkinson's disease, become more prevalent with an aging global population. Innovations in biomarker ...